Cd33 specific chimeric antigen receptors
AssigneePrecigen, Inc.
InventorsRutul SHAH, Tim CHAN, Peter EMTAGE, Ramya YARLAGADDA
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
Claims30
1-13. (canceled)
A vector comprising a backbone and a nucleic acid sequence encoding:
- (a) a truncated epidermal growth factor receptor comprising a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO:
- 32;
- and
- (b) a chimeric antigen receptor (CAR) comprising:
- a CD33 antigen binding domain;
- a transmembrane domain;
- and an intercellular signaling domain.
A vector comprising a backbone and a nucleic acid sequence encoding:
- (a) a full length CD20, a truncated CD20 (CD20t-1), or a functional variant of CD20;
- and
- (b) a chimeric antigen receptor (CAR) comprising:
- a CD33 antigen binding domain;
- a transmembrane domain;
- and an intercellular signaling domain.
(canceled)
19-22. (canceled)
(canceled)
27-35. (canceled)
37-41. (canceled)
(canceled)
45-52. (canceled)
54-65. (canceled)
68-73. (canceled)
A vector comprising a backbone and a nucleic acid sequence encoding:
- (a) a cytokine;
- and (b) a chimeric antigen receptor comprising a CD33 antigen binding domain, a transmembrane domain, and an intracellular signaling domain.
A composition comprising a cell expressing:
- (a) a truncated epidermal growth factor receptor;
- and (b) a chimeric antigen receptor comprising a CD33 antigen binding domain, a transmembrane domain, and an intracellular signaling domain.
Dependencies are inferred from the claim text.